Exenatide - Pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 2, 2011, Pages 99-108

  Linnebjerg, H ^a   Kothare, P A ^a   Seger, M ^a   Wolka, A M ^a   Mitchell, M I ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Elderly; Exenatide; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; PLACEBO;

AGE; AGED; APPETITE; ARTICLE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG INJECTION VOLUME; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; KIDNEY CLEARANCE; KIDNEY FUNCTION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; RACE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VITAL SIGN; VOMITING;

AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 78751683801     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201361     Document Type: Article

References (30)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225-232.
2. Byetta prescribing information. Available online at: pi.lilly.com/us/ byetta-pi.pdf. Accessed 23 June 2010.
3. Bastyr EJ 3rd, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care. 2000; 23: 1236-1241.
4. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005; 45: 570-577. (Pubitemid 40562948)
5. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628-2635.
6. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005; 27: 210-215. (Pubitemid 40462014)
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
8. DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHOand American Diabetic Association diagnostic criteria. Lancet. 1999; 354: 617-621.
9. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28: 1092-1100. (Pubitemid 40616618)
10. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004; 53: 2397-2403.
11. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus preprandial glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995; 333: 1237-1241.
12. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003; 26: 2929-2940. (Pubitemid 37205571)
13. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003; 26: 2370-2377. (Pubitemid 36993328)
14. Fineman M, Phillips L, Jaworowicz DJ, Cirincione B, Ludwig E, Taylor K, Kothare PA, Baron AD, Grasela T. Model-based evaluations to select and confirm doses in the clinical development of exenatide. Clin Pharmacol Ther. 2007; 81 (Suppl 111): Abstract PIII-82.
15. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-1091. (Pubitemid 40616617)
16. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 3082-3089.
17. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005; 62: 173-181.
18. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007; 64: 317-327.
19. Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract. 2007; 61 (Suppl 154): 29-37.
20. Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care. 1997; 20: 135-141.
21. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes. 1994; 43: 403-410.
22. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci. 2001; 56: 5-13.
23. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res. 2001; 53: 260-267. (Pubitemid 33029654)
24. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996; 44: 871-872.
25. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997; 157: 1681-1686.
26. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia. 2006; 49: 706-712.
27. Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care. 2007; 13 (Suppl 2): 47-54.
28. US [CDC] Centers forDisease Control and Prevention. Diabetes data & trends. Available online at: http://www.cdc.gov/diabetes/statistics/cvd/fig4. htm. Accessed 23 June 2010.
29. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG. The aging kidney. Kidney Int. 2008; 74: 710-720.
30. Zinman B, Hoogwerf BJ, Durán Garcia S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 146: 477-485.